Market Cap: $277.23B
Market Cap: $277.23B

AstraZeneca PLC ( AZN ) is navigating a multifaceted landscape marked by both challenges and growth opportunities. The company's recent performance highlights a robust strategy aimed at overcoming obs…

AstraZeneca PLC ( AZN ) is at the forefront of transformative developments that could reshape its presence in the global pharmaceutical landscape. Current reports indicate that AstraZeneca is in talks…

AstraZeneca PLC AZN is navigating a challenging landscape as it seeks to maintain its reputation for innovative drug development and aggressive growth targets. This comes in the wake of recent setback…

Astrazeneca plc (Ticker: AZN) partners with ZERO Prostate Cancer on a transformative initiative aimed at improving prostate cancer care. Joining Forces to Combat Disparities The Blitz the Barriers pro…

Astrazeneca plc (Ticker: AZN) actively participates in enhancing prostate cancer care through its partnership with ZERO Prostate Cancer in the newly launched initiative named Blitz the Barriers. This…

AstraZeneca plc (Ticker: AZN) actively partners with the Lung Cancer Research Foundation (LCRF) to enhance treatment outcomes for patients suffering from small cell lung cancer (SCLC). On June 9, 2026…

AstraZeneca plc (Ticker: AZN) collaborates with the Lung Cancer Research Foundation to address the urgent need for innovative treatments for small cell lung cancer (SCLC). The joint initiative announc…
AstraZeneca plc (Ticker: AZN) announces promising results from its Phase 3 CALYPSO trial for eneboparatide, a treatment targeting chronic hypoparathyroidism. The trial reveals that 31.1% of patients o…

AstraZeneca achieves a significant milestone with its prostate cancer drug Truqap (capivasertib). A recent FDA advisory panel votes 7-1, with one abstention, to recognize its favorable benefit-risk pr…
AstraZeneca's Breakthrough in Chronic Obstructive Pulmonary Disease Treatment AstraZeneca's recent announcement regarding the efficacy of its experimental drug Tozorakimab marks a significant advancem…
Innovative Solutions to Prescription Drug Affordability: A Shift in Healthcare Economics The pharmaceutical landscape faces intensifying scrutiny due to rising prescription drug costs, leading to sign…
AstraZeneca Enhances Accessibility Through Expanded Discounted Medication Offerings In a strategic move to improve health outcomes, AstraZeneca plc significantly expands its range of discounted prescr…
AstraZeneca Expands Affordability Initiatives for Prescription Medications In a significant move to enhance accessibility in the pharmaceutical landscape, AstraZeneca plc announces a substantial expan…
AstraZeneca's Strategic Interest in Abivax: A Potential Acquisition on the Horizon? AstraZeneca Plc, the British pharmaceutical giant, emerges as a leading contender for the potential acquisition of F…
AstraZeneca Eyes Strategic Acquisition of Abivax Amid Biotech Boom AstraZeneca plc is strategically positioning itself to lead a potential acquisition of French biotech firm Abivax SA, following a not…
AstraZeneca's Strategic Interest in Abivax: A Potential Shift in Biotech Dynamics AstraZeneca Plc is emerging as a leading contender in the potential acquisition of French biotech firm Abivax SA. This…
### AstraZeneca: Strengthening Its Position in the Competitive Vaccine Landscape AstraZeneca continues to reinforce its leading position in the pharmaceutical industry, particularly within the vaccine…
AstraZeneca’s Resilience Amid Evolving Market Dynamics In recent weeks, AstraZeneca plc showcases significant resilience as the pharmaceutical and vaccine landscape faces evolving challenges. Amidst a…
AstraZeneca Empowers Vaccine Strategies Amidst Market Challenges AstraZeneca plc asserts its position in the competitive pharmaceutical landscape as it adapts its strategies following recent industry…
### AstraZeneca Partners with Lung Cancer Research Foundation to Transform SCLC Treatment In a significant development for lung cancer treatment, AstraZeneca collaborates with the Lung Cancer Research…
AstraZeneca Partners with LCRF to Tackle Small Cell Lung Cancer In a significant move to enhance treatment options for small cell lung cancer (SCLC), AstraZeneca has entered into a collaboration with…
AstraZeneca steps up digital-health push as tech confidence mounts AstraZeneca is increasingly framing its drug development and patient-engagement strategies around partnerships with major technology…
AstraZeneca reinforces innovation and digital health as tech wins headlines AstraZeneca is reinforcing its research-and-development narrative and digital-health initiatives as public commentary around…
Investor commentary on big tech prompts strategic focus across pharma A brief on-air endorsement of Apple by a prominent wealth manager is sharpening attention on sector dynamics and prompting pharmac…
TrumpRx pushes AstraZeneca into a public pricing test A federal platform launched last week, TrumpRx.gov, places AstraZeneca among five drugmakers offering discounted, government‑listed prices for an…
Rate signal tests drugmakers' cost profiles U.S. Jobs and CPI Data Loom as Rate Signal for Pharmaceuticals A heavy U.S. data week, anchored by the January employment report midweek and the January con…
Macro data week looms over AstraZeneca’s cost and pricing outlook AstraZeneca faces a week of U.S. labour and inflation releases that are shaping its near‑term operating environment, with implications…
Washington presses global drugmakers with new TrumpRx.gov rollout The White House launches TrumpRx.gov as an administration-backed portal offering consumers access to prescription medicines at prices…
White House unveils TrumpRx site to push down U.S. drug costs Pharmaceutical industry focus turns to a new White House initiative as the administration launches TrumpRx.gov, a government-backed portal…
AstraZeneca Secures Global Rights for Innovative Cancer Therapy AstraZeneca has solidified its position in the oncology space by acquiring the global development and commercialization rights for C-CAR…
AstraZeneca Expands Global Reach with C-CAR031 Acquisition AstraZeneca plc has made a significant move in the biopharmaceutical landscape by acquiring the remaining 50% share of the development and co…
AstraZeneca Expands Global Reach in CAR-T Therapy for Liver Cancer AstraZeneca plc solidifies its position in the CAR-T therapy landscape by acquiring full rights to C-CAR031, a promising treatment ta…
AstraZeneca Faces Competition in the Evolving GLP-1 Market AstraZeneca plc finds itself in a rapidly changing landscape as the GLP-1 market transitions from traditional weekly injection therapies to m…
Oral GLP-1 Medications Poised to Transform Obesity Treatment Landscape In a significant shift within the obesity treatment market, the introduction of oral GLP-1 medications marks a transformative mom…
AstraZeneca's Strategic Focus on Autoimmune Diseases and Innovative Therapies AstraZeneca plc recognizes the growing demand for effective treatments in the realm of autoimmune diseases, a sector that…
AstraZeneca's Breakthrough in Lupus Treatment: TULIP-SC Trial Results Unveiled AstraZeneca Plc announces significant advancements in the treatment of systemic lupus erythematosus (SLE) with the full r…
AstraZeneca Advances Autoimmune Treatment with Anifrolumab Results AstraZeneca Plc announces the full results of its Phase 3 TULIP-SC trial, showcasing a significant development in the treatment of sy…
Judicial Ruling Sparks Debate Over 340B Drug Pricing Program Modifications A federal judge recently issues a temporary injunction against the U.S. administration's 340B Rebate Model Pilot Program, whi…
Judicial Ruling Highlights Challenges in Drug Pricing Reforms A recent federal court ruling brings to the forefront the complexities and legal requirements surrounding the U.S. government's 340B Drug…
AstraZeneca Faces Competition in the Expanding GLP-1 Market AstraZeneca plc finds itself in a rapidly changing landscape as the approval of Novo Nordisk's oral Wegovy captures the attention of both he…
AstraZeneca Faces Competitive Landscape in GLP-1 Market Amid Novo Nordisk's Oral Wegovy Approval The recent approval of Novo Nordisk's oral Wegovy has significant implications for the pharmaceutical i…
AstraZeneca's Proactive Withdrawal of Andexxa Highlights Commitment to Patient Safety AstraZeneca Plc, a leading entity in the pharmaceutical industry, is taking decisive action following the U.S. Foo…
AstraZeneca Faces Regulatory Setback with Andexxa Withdrawal In a significant development for AstraZeneca plc, the company voluntarily withdraws its biologics license for Andexxa, a drug that has rece…
### AstraZeneca's Proactive Approach to Drug Safety: The Withdrawal of Andexxa In a recent development, AstraZeneca Plc has announced its decision to voluntarily withdraw the biologics license for And…
AstraZeneca Advances Cancer Treatment Through Strategic Collaboration with Compugen AstraZeneca has entered into a significant strategic agreement with Compugen Ltd. to enhance the commercial potentia…
AstraZeneca Partners with Compugen to Advance Rilvegostomig Development AstraZeneca's recent strategic agreement with Compugen Ltd. marks a significant milestone in the development of rilvegostomig, a…
AstraZeneca and Compugen Forge Strategic Alliance for Cancer Therapy Development AstraZeneca PLC has secured a non-dilutive strategic agreement with Compugen Ltd. to enhance the development and commer…
GSK's Approval of Gepotidacin: A New Hope in Gonorrhoea Treatment In a pivotal move against the rising threat of antibiotic-resistant gonorrhoea, the U.S. Food and Drug Administration (FDA) grants GSK…
AstraZeneca's Short Interest Decline Signals Shift in Investor Confidence AstraZeneca PLC experiences a notable decrease in short interest, with figures reporting a 6.25% drop since the last report. C…
AstraZeneca Sees Shift in Investor Sentiment Amid Declining Short Interest AstraZeneca PLC has recently reported a notable decrease in its short interest as a percentage of float, dropping by 6.25%. T…